Mike Thompson MBE joins Albert Labs as a prominent figure in Healthcare and Pharmaceuticals, bringing twenty-five years of experience in the Life Sciences sector. Between 2016 and 2019, Mike served as CEO at The Association of the British Pharmaceutical Industry (ABPI) and previously held senior positions at GSK in Global, European Regional and UK levels of the company. In 2021 Mike was awarded an MBE for services to medicines supply and resilience in the Queen’s Birthday Honours List.

During his time as CEO at the ABPI, Mike was at the forefront of UK drug approval and pricing policy, working hand-in-hand with Government bodies on behalf of the pharmaceutical industry. Amongst a number of considerable achievements in this role, Mike oversaw the agreement for £60bn of expenditure on branded pharmaceuticals, working closely with 10 Downing Street, HM Treasury and the Department of Health and Social Care.

Mike Thompson, MBE said: “Whilst enormous progress has been made in recent years in prolonging life for many cancer patients, both clinicians and the life sciences industry are well aware of the significant gap that still remains in alleviating related mental health distress. I’m delighted to be joining Albert Labs to help them bring their KRN-101 asset to market.”